English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Aims  The audit was carried out to determine the frequency of off label prescribing of quetiapine and compliance with standards within Trust Policy (UHM PGN 02 PPT PGN 08) – Physical Health Monitoring of Patients Prescribed Antipsychotics and other Psychotropic Medicines, NICE CG178, General Medical Council Ethical Standards and Royal College of Psychiatrists – College Report CR210.  The main objectives of the audit were to determine if:  Patients have been appropriately informed of off-label status and consent recorded.  Alternative licensed treatment first used/ruled out.  Appropriate communication on transfer of care.  Appropriate physical health monitoring completed.    Background  Quetiapine is associated with various physical side effects. Patients should be fully informed of the expected risks and benefits of treatment, and the limited evidence base for off-label prescribing.  There are additional issues around the transfer of prescribing to primary care.    Method  The sample consisted of 50 consecutive patients selected from the crisis team caseload in the month of December 2018.  Data reviewed in this audit were taken from six months period.  Records audited were obtained from RiO (electronic records) and prescription charts.  Data collection was started in January 2019 and completed in March 2019  The audit tool was a dichotomous scale questionnaire based on NICE guidelines.    Result  4 patients from the sample (8%) were prescribed off-label quetiapine.  100% had physical health monitoring completed as per Trust policy.  100% off-label indication been clearly documented in notes.  100% Consent to treatment was documented.  100% had medication reviewed in the previous 6 months.  75% had licensed medication used or ruled out before considering off-label quetiapine use  25% risks/benefits of treatment were documented as part of a patient discussion.  25% had documented evidence that alternative treatment options were discussed.  25% had documented evidence of Community consultant/GP consent/agreement was obtained before transfer of prescribing  75% had a documented plan for review of quetiapine for treatment efficacy and side effects  50% had a documented plan in place for ongoing physical health monitoring    Conclusion  Suggested a wider audit may be required with greater patient numbers and which specifically filters for patients prescribed quetiapine.  Audit result has been shared with Crisis team members, Medicines Optimisation Committee and South Locality Quality Standards Committee in the trust.

Off-label prescribing of quetiapine in south locality crisis teams